Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. reports news on its medical supplies business, centered on insulin delivery products and diabetes-care devices. The company sells pen needles, syringes and safety devices through wholesalers, distributors and institutional channels, and it has described a transition from insulin delivery toward a broader medical supplies platform.
Recurring updates include quarterly operating and financial results, cash dividend declarations, conference participation, board leadership changes, operational updates, capital-structure matters, material agreements, and regulatory or clinical disclosures tied to its device portfolio and manufacturing activities.
embecta (Nasdaq: EMBC) announced on Nov 14, 2025 a major expansion of its humanitarian partnership with Direct Relief to increase global and U.S. access to diabetes injection devices. Following a North America packaging transition, embecta donated approximately 15 million pen needles and insulin syringes and will continue support through 2026.
The commitment funds emergency response, supports more than 1,600 community health centers serving ~36 million patients, aids the Life for a Child program (53,000+ children in 45 countries), and included a recent 2.7 million unit donation for Sudan; embecta also provided a July 2025 grant of $25,000 for Texas storm relief.
embecta (Nasdaq: EMBC) will report fiscal fourth quarter and full year 2025 results and host a conference call at 8:00 a.m. ET on Tuesday, November 25, 2025. The company says the call will include an operational update and preliminary fiscal year 2026 financial guidance.
Investors can join a live webcast or teleconference via the company’s investor website at investors.embecta.com. A webcast replay will be available beginning at 11:00 a.m. ET on November 25, 2025 and will be archived on the investor site for one year.
Embecta (Nasdaq: EMBC), a medical supplies company specializing in insulin delivery, has announced its participation in two major healthcare investor conferences in September 2025.
At the 2025 Wells Fargo Healthcare Conference on September 4, management will host a fireside chat at 3:00 p.m. EDT and conduct one-on-one investor meetings at the Encore Boston Harbor Hotel. The company will also participate in the 2025 Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, hosting one-on-one investor meetings at the Sheraton New York Times Square.
Embecta (NASDAQ:EMBC) reported strong Q3 fiscal 2025 results with revenues of $295.5 million, up 8.4% year-over-year. The company achieved notable growth in both U.S. (11.6%) and International (5.0%) markets. Key financial metrics include adjusted operating income of $109.1 million with a 36.9% margin, and adjusted earnings per share of $1.12, up from $0.74 in the prior year.
The company completed several strategic initiatives, including implementing their ERP system and operationalizing distribution centers in India. Embecta also made progress in co-packaging agreements for GLP-1 drugs and reduced debt by $52.4 million during Q3, bringing year-to-date debt reduction to $112 million. The company declared a quarterly dividend of $0.15 per share and raised its fiscal 2025 guidance.
Embecta (Nasdaq: EMBC) has announced its Board of Directors has declared a quarterly cash dividend of $0.15 per share for its common stock. The dividend will be paid on September 15, 2025, to shareholders of record as of the close of business on August 29, 2025.
Embecta (Nasdaq: EMBC), a medical supplies company specializing in insulin delivery, has scheduled its fiscal third quarter 2025 financial results conference call for August 8, 2025, at 8:00 a.m. ET. The company will present financial results, provide operational updates, and host a Q&A session.
Investors can access the presentation through a live webcast or teleconference. A replay will be available from 11:00 a.m. ET on the same day through the company's investor relations website, where it will remain archived for one year.
Embecta (NASDAQ: EMBC), a medical supplies company specializing in insulin delivery, has announced its participation in four major investor conferences in May and June 2025:
- Goldman Sachs Leveraged Finance Conference (May 29) - One-on-one meetings in Dana Point, CA
- Jefferies Global Healthcare Conference (June 5) - Fireside session at 4:55 PM EDT in NYC
- Goldman Sachs Global Healthcare Conference (June 10) - Fireside session at 1:20 PM EDT in Miami
- Truist Securities MedTech Conference (June 17) - One-on-one meetings in Boston
Embecta (Nasdaq: EMBC) has announced its Board of Directors has declared a quarterly cash dividend of $0.15 per share for all outstanding common stock. The dividend will be paid on June 13, 2025 to stockholders who are on record as of the close of business on May 28, 2025.
Embecta (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced its upcoming Analyst and Investor Day scheduled for May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City.
The event will feature presentations from President & CEO Dev Kurdikar, CFO Jake Elguicze, and other leadership team members. They will discuss:
- Strategic and business overview
- Value creation opportunities
- Company's financial profile
- Long-term objectives
While in-person attendance is by invitation only, interested parties can participate via webcast through InvestorDay.embecta.com. A replay and presentation materials will be available in the 'Events & Presentations' section of the company's Investor Relations website after the event.